These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 7951498)

  • 1. Intravenous methylprednisolone pulse therapy for Graves' ophthalmopathy.
    Hiromatsu Y; Tanaka K; Sato M; Kuroki T; Nonaka K; Kojima K; Nishimura H; Nishida H; Kaise N
    Endocr J; 1993 Feb; 40(1):63-72. PubMed ID: 7951498
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationship between longitudinal behaviour of some markers of eye autoimmunity and changes in ocular findings in patients with Graves' ophthalmopathy receiving corticosteroid therapy.
    De Bellis A; Bizzarro A; Conte M; Coronella C; Solimeno S; Perrino S; Sansone D; Guaglione M; Wall JR; Bellastella A
    Clin Endocrinol (Oxf); 2003 Sep; 59(3):388-95. PubMed ID: 12919164
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thyroid stimulating antibody in sera of Graves' ophthalmopathy patients as a possible marker for predicting the efficacy of methylprednisolone pulse therapy.
    Mori S; Yoshikawa N; Horimoto M; Yoshimura M; Ogawa Y; Nishikawa M; Inada M
    Endocr J; 1995 Jun; 42(3):441-8. PubMed ID: 7670573
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Prediction for effectiveness of steroid pulse therapy by MRI in Graves' ophthalmopathy].
    Sato M; Hiromatsu Y; Tanaka K; Nonaka K; Kojima K; Nishimura H; Nishida H
    Nihon Naibunpi Gakkai Zasshi; 1992 Mar; 68(3):143-53. PubMed ID: 1582520
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Treatment of Grave's ophthalmopathy with high doses of corticosteroids].
    Cirić J; Zarković M; Stojanović M; Pepenezić Z; Randjelović G; Gligorović M; Trbojević B; Drezgić M; Nesović M
    Srp Arh Celok Lek; 2000; 128(5-6):179-83. PubMed ID: 11089418
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of high-dose intravenous steroid pulse therapy followed by 3-month oral steroid therapy for Graves' ophthalmopathy.
    Ohtsuka K; Sato A; Kawaguchi S; Hashimoto M; Suzuki Y
    Jpn J Ophthalmol; 2002; 46(5):563-7. PubMed ID: 12457917
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of steroid pulse therapy with and without orbital radiotherapy on Graves' ophthalmopathy.
    Ohtsuka K; Sato A; Kawaguchi S; Hashimoto M; Suzuki Y
    Am J Ophthalmol; 2003 Mar; 135(3):285-90. PubMed ID: 12614743
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of Graves' ophthalmopathy with high-dose intravenous methylprednisolone pulse therapy.
    Nagayama Y; Izumi M; Kiriyama T; Yokoyama N; Morita S; Kakezono F; Ohtakara S; Morimoto I; Okamoto S; Nagataki S
    Acta Endocrinol (Copenh); 1987 Dec; 116(4):513-8. PubMed ID: 3321820
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravenous methylprednisolone in the treatment of Graves' ophthalmopathy.
    Kendall-Taylor P; Crombie AL; Stephenson AM; Hardwick M; Hall K
    BMJ; 1988 Dec; 297(6663):1574-8. PubMed ID: 2906260
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravenous methylprednisolone pulse therapy in the treatment of Graves' ophthalmopathy.
    Matejka G; Vergès B; Vaillant G; Petit JM; Brun-Pacaud A; Rudoni S; Brun JM
    Horm Metab Res; 1998 Feb; 30(2):93-8. PubMed ID: 9543692
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined cyclosporin-A and methylprednisolone treatment of Graves' ophthalmopathy.
    Leövey A; Bakó G; Szabó J; Kálmán K; Fórizs E
    Acta Med Hung; 1992-1993; 49(3-4):179-85. PubMed ID: 1345455
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Graves' ophthalmopathy: eye muscle involvement in patients with diplopia.
    Nagy EV; Toth J; Kaldi I; Damjanovich J; Mezosi E; Lenkey A; Toth L; Szabo J; Karanyi Z; Leovey A
    Eur J Endocrinol; 2000 Jun; 142(6):591-7. PubMed ID: 10832104
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High dose intravenous methylprednisolone pulse therapy versus oral prednisone for thyroid-associated ophthalmopathy.
    Kauppinen-Mäkelin R; Karma A; Leinonen E; Löyttyniemi E; Salonen O; Sane T; Setälä K; Viikari J; Heufelder A; Välimäki M
    Acta Ophthalmol Scand; 2002 Jun; 80(3):316-21. PubMed ID: 12059873
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-dose intravenous steroid pulse therapy in thyroid-associated ophthalmopathy.
    Tagami T; Tanaka K; Sugawa H; Nakamura H; Miyoshi Y; Mori T; Nakao K
    Endocr J; 1996 Dec; 43(6):689-99. PubMed ID: 9075609
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma exchange therapy for severe Graves' ophthalmopathy.
    Glinoer D; Schrooyen M
    Horm Res; 1987; 26(1-4):184-9. PubMed ID: 3596467
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-eye muscle antibodies and hypothyroid Graves' disease: a case report.
    Hiromatsu Y; Sato M; Tanaka K; Nonaka K; Kojima K; Sato K; Kurose S; Hoshino T; Nakashima A
    Endocrinol Jpn; 1992 Dec; 39(6):593-600. PubMed ID: 1363467
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Three dimensional orbital magnetic resonance T2-mapping in the evaluation of patients with Graves' ophthalmopathy.
    Hou K; Ai T; Hu WK; Luo B; Wu YP; Liu R
    J Huazhong Univ Sci Technolog Med Sci; 2017 Dec; 37(6):938-942. PubMed ID: 29270757
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapy of Graves' ophthalmopathy with intravenous high-dose steroid followed by orbital irradiation.
    Koshiyama H; Koh T; Fujiwara K; Hayakawa K; Shimbo S; Misaki T
    Thyroid; 1994; 4(4):409-13. PubMed ID: 7711503
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early response to intravenous glucocorticoids for severe thyroid-associated ophthalmopathy predicts treatment outcome.
    Hart RH; Kendall-Taylor P; Crombie A; Perros P
    J Ocul Pharmacol Ther; 2005 Aug; 21(4):328-36. PubMed ID: 16117697
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Extraocular muscle antibodies and the occurrence of ophthalmopathy in Graves' disease.
    de Bellis A; Perrino S; Coronella C; Sansone D; Ruocco G; Tirelli G; Di Martino S; Conte M; Bellastella G; Wall JR; Bellastella A; Bizzarro A
    Clin Endocrinol (Oxf); 2004 Jun; 60(6):694-8. PubMed ID: 15163332
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.